N. Bud Grossman Center, University of Minnesota, Minneapolis, MN 55455, United States.
Neurobiol Aging. 2011 Oct;32(10):1784-94. doi: 10.1016/j.neurobiolaging.2009.11.007. Epub 2010 Jan 19.
Soluble forms of amyloid-β peptide (Aβ) are a molecular focus in Alzheimer's disease research. Soluble Aβ dimers (≈8 kDa), trimers (≈12 kDa), tetramers (≈16 kDa) and Aβ56 (≈56 kDa) have shown biological activity. These Aβ molecules have been derived from diverse sources, including chemical synthesis, transfected cells, and mouse and human brain, leading to uncertainty about toxicity and potency. Herein, synthetic Aβ peptide-derived oligomers, cell- and brain-derived low-n oligomers, and Aβ56, were injected intracerebroventricularly (icv) into rats assayed under the Alternating Lever Cyclic Ratio (ALCR) cognitive assay. Cognitive deficits were detected at 1.3 μM of synthetic Aβ oligomers and at low nanomolar concentrations of cell-secreted Aβ oligomers. Trimers, from transgenic mouse brain (Tg2576), did not cause cognitive impairment at any dose tested, whereas Aβ*56 induced concentration-dependent cognitive impairment at 0.9 and 1.3μM. Thus, while multiple forms of Aβ have cognition impairing activity, there are significant differences in effective concentration and potency.
淀粉样β肽(Aβ)的可溶性形式是阿尔茨海默病研究的分子焦点。可溶性 Aβ 二聚体(≈8 kDa)、三聚体(≈12 kDa)、四聚体(≈16 kDa)和 Aβ56(≈56 kDa)已显示出生物活性。这些 Aβ 分子来自多种来源,包括化学合成、转染细胞以及小鼠和人脑,导致其毒性和效力存在不确定性。在此,通过交替杠杆循环比(ALCR)认知测定,将合成 Aβ 肽衍生的低聚物、细胞和脑衍生的低聚物以及 Aβ56 注入大鼠的侧脑室(icv)中进行分析。在 1.3 μM 的合成 Aβ 低聚物和低纳摩尔浓度的细胞分泌 Aβ 低聚物时,检测到认知缺陷。来自转基因小鼠脑(Tg2576)的三聚体在测试的任何剂量下均未引起认知障碍,而 Aβ*56 在 0.9 和 1.3μM 时引起浓度依赖性认知障碍。因此,虽然 Aβ 的多种形式具有认知损伤活性,但有效浓度和效力存在显著差异。